Growth hormone deficiency (GHD) therapeutics pipeline is predicted to increase in future mainly due to the increasing prevalence of the disease, globally. The major factors driving the pipeline of growth hormone deficiency include, increasing prevalence of pituitary dysfunction, low market penetration as very limited number of companies are making an analog of growth hormone. The rising affordability of the drugs and increasing geriatric population also serve as major factors leading to growth of the pipeline. According to the Human Growth Foundation, it is estimated that growth hormone deficiency occurs in children between 1 to 4,000 to 1 to 10,000, in the U.S. There are more than 50,000 adults associated with growth hormone deficiency and around 6,000 new cases are being reported per year.
Growth hormone is a major body system metabolic hormone that controls lipid, protein and carbohydrate homeostasis. The principal form of growth hormone is around 22 kD and contains 191 amino acids, known as somatotrope. This hormone is produced by growth hormone cells known as somatotropes located in adenohypophysis of pituitary gland. Growth hormone deficiency is classified into four categories as pituitary or classic GHD, hypothalamic GHD, functional growth hormone deficiency and idiopathic GHD. In case of pituitary GHD, there is an abnormality in brain, due to which there is an incapacity to produce growth hormone. Hypothalamic GHD occurs when there is failure of hypothalamic function of transmitting neurocrine messaging hormone, which directs the pituitary gland to produce growth hormone. Functional GHD occurs when other metabolic hormone fails to secrete or impaired metabolic function due to various unknown etiologies. Idiopathic GHD occurs due to unknown causes. There are various psychological symptoms that occur in growth hormone deficiency such as depression, lack of concentration, emotional distress and poor memory. The disease can also lead to increased fat mass and extra cellular fluid volume, diminished muscle strength and stamina, lethargy and depression.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/growth-hormone-deficiency-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of growth hormone deficiency therapeutic pipeline analysis include Merck Serono, Pfizer, Inc., Novo Nordisk, F. Hoffman-La Roche AG, Eli lilly and Company, Ferring pharmaceuticals, Inc. LG Life Sciences Pvt. Ltd., Sandoz Internatinal, Teva Pharmaceutical industries, OPKO Health, Inc., AnkeBio Co., Ltd.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)